WD Rutherford LLC Purchases 7,190 Shares of Boston Scientific Corporation $BSX

Key Points

• WD Rutherford LLC increased its stake in Boston Scientific Corporation (BSX) by 77.8%, acquiring 7,190 additional shares, bringing its total holdings to 16,435 shares valued at approximately $1.77 million.
• Several institutional investors, including GAMMA Investing LLC and Vanguard Group Inc., significantly boosted their stakes in Boston Scientific during the first quarter, indicating strong investor confidence; 89.07% of the stock is currently owned by institutional investors.
• Boston Scientific reported a 22.8% increase in revenue year-over-year in its recent earnings, surpassing analyst expectations with a reported EPS of $0.75 against estimates of $0.72.

WD Rutherford LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 77.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,435 shares of the medical equipment provider's stock after acquiring an additional 7,190 shares during the period. WD Rutherford LLC's holdings in Boston Scientific were worth $1,765,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. GAMMA Investing LLC increased its stake in Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after acquiring an additional 2,556,078 shares during the period. Vanguard Group Inc. increased its stake in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock valued at $250,757,000 after purchasing an additional 1,536,663 shares during the period. Finally, Swedbank AB grew its stake in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock valued at $302,816,000 after purchasing an additional 1,505,019 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 in the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 0.1%

NYSE BSX opened at $98.20 on Friday. The firm has a market cap of $145.51 billion, a PE ratio of 58.45, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The stock's 50 day simple moving average is $103.79 and its 200 day simple moving average is $102.11. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BSX. Robert W. Baird upped their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. BTIG Research reiterated a "buy" rating and issued a $127.00 price objective on shares of Boston Scientific in a research note on Tuesday, September 23rd. Finally, Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $118.17.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.